A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: blob (6), smudge (1), smear (12), blot (1)

MyelomaPAD-Bortezomib(SC)DexamethasoneDoxorubicinVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA PAD (SC)-BORTEZOMIB (SC)-DEXAMETHASONE-DOXORUBICIN Regimen Multiple Myeloma – PAD (SC)-Bortezomib (SC)-Dexamethasone-Doxorubicin Indication Second
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaPAD-BortezomibSCDexamethasoneDoxorubicinVer1.pdf

MyelomaPAD-Bortezomib(IV)DexamethasoneDoxorubicinVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA PAD (IV)-BORTEZOMIB (IV)-DEXAMETHASONE-DOXORUBICIN Regimen Multiple Myeloma – PAD (IV)-Bortezomib (IV)-Dexamethasone-Doxorubicin Indication Second
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaPAD-BortezomibIVDexamethasoneDoxorubicinVer1.pdf

MyelomaMPVBortezomib(SC)MelphalanPrednisolone(35day)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA MPV (SC)-BORTEZOMIB (SC)-MELPHALAN (PO)-PREDNISOLONE (35 day) Regimen Multiple Myeloma – MPV(SC)-Bortezomib (SC)-Melphalan
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPVBortezomibSCMelphalanPrednisolone35dayVer1.pdf

MyelomaMPVBortezomib(IV)MelphalanPrednisolone(35day)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA MPV (IV)-BORTEZOMIB (IV)-MELPHALAN (PO)-PREDNISOLONE (35 day) Regimen Multiple Myeloma – MPV(IV)-Bortezomib (IV)-Melphalan
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPVBortezomibIVMelphalanPrednisolone35dayVer1.pdf

Dabrafenib Trametinib Ver1

Description
Chemotherapy Protocol SKIN CANCER DABRAFENIB-TRAMETINIB Regimen  Skin – Dabrafenib-Trametinib Indication  The combination of dabrafenib and trametinib is recommended as an
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinDabrafenibTrametinibVer1.pdf

Fulvestrant-Palbociclib

Description
Chemotherapy Protocol Breast Cancer Fulvestrant-Palbociclib Regimen • Breast Cancer – Fulvestrant-Palbociclib Indication Palbociclib with fulvestrant is recommended for use within the
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Fulvestrant-Palbociclib.pdf

HSCTMelphalan-Bortezomib IV

Description
Chemotherapy Protocol HAEMATOLOGY – HSCT AUTOGRAFT InP - MELPHALAN and BORTEZOMIB (IV) Please confirm correct protocol with transplant schedule Regimen • HSCT – InP - Melphalan
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTMelphalan-Bortezomib-IV.pdf

Cytarabine_2000_FludarabineIdarubicin_FLA-Ida

Description
Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA CYTARABINE (2000)-FLUDARABINE-IDARUBICIN (FLA-IDA) In-Patient Regimen Regimen • Acute Myeloid Leukaemia – InP-Cytarabine (2000
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Cytarabine-2000-FludarabineIdarubicin-FLA-Ida.pdf

Cytarabine_1000_FludarabineIdarubicin_FLA-Ida

Description
Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA CYTARABINE (1000)-FLUDARABINE-IDARUBICIN (FLA-IDA) In-Patient Regimen Regimen • Acute Myeloid Leukaemia – InP-Cytarabine (1000
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Cytarabine-1000-FludarabineIdarubicin-FLA-Ida.pdf

Erdafitinib

Description
Regimen • Urothelial - Erdafitinib Chemotherapy Protocol UROTHELIAL CANCER ERDAFITINIB Indication • Monotherapy treatment of unresectable or metastatic urothelial cancer harbouring a susceptible fibroblast
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Erdafitinib.pdf
51 to 60 of 90
Previous … 4 5 6 7 8 … Next